NO20061541L - Behandling av gastroparese og ikke-ulceros dyspepsi med GABAB-agonister - Google Patents
Behandling av gastroparese og ikke-ulceros dyspepsi med GABAB-agonisterInfo
- Publication number
- NO20061541L NO20061541L NO20061541A NO20061541A NO20061541L NO 20061541 L NO20061541 L NO 20061541L NO 20061541 A NO20061541 A NO 20061541A NO 20061541 A NO20061541 A NO 20061541A NO 20061541 L NO20061541 L NO 20061541L
- Authority
- NO
- Norway
- Prior art keywords
- gastroparesis
- treatment
- baclofen
- methods
- formulations
- Prior art date
Links
- 206010021518 Impaired gastric emptying Diseases 0.000 title abstract 2
- 201000006549 dyspepsia Diseases 0.000 title abstract 2
- 208000001288 gastroparesis Diseases 0.000 title abstract 2
- 208000025865 Ulcer Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 abstract 2
- 229960000794 baclofen Drugs 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- KPYSYYIEGFHWSV-QMMMGPOBSA-N Arbaclofen Chemical compound OC(=O)C[C@@H](CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-QMMMGPOBSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50224203P | 2003-09-12 | 2003-09-12 | |
US55394004P | 2004-03-18 | 2004-03-18 | |
PCT/IB2004/003299 WO2005025559A1 (en) | 2003-09-12 | 2004-09-10 | Treatment of gastroparesis and nonulcer dyspepsia with gabab agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20061541L true NO20061541L (no) | 2006-04-05 |
Family
ID=34316518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20061541A NO20061541L (no) | 2003-09-12 | 2006-04-05 | Behandling av gastroparese og ikke-ulceros dyspepsi med GABAB-agonister |
Country Status (9)
Country | Link |
---|---|
US (2) | US20050090554A1 (es) |
EP (1) | EP1675581A1 (es) |
JP (1) | JP2007505099A (es) |
AU (1) | AU2004271805A1 (es) |
CA (1) | CA2537343A1 (es) |
IL (1) | IL173930A0 (es) |
MX (1) | MXPA06002572A (es) |
NO (1) | NO20061541L (es) |
WO (1) | WO2005025559A1 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7824697B2 (en) | 2004-07-12 | 2010-11-02 | Board Of Regents, The University Of Texas System | High concentration baclofen preparations |
AU2007201808B8 (en) * | 2006-04-26 | 2013-09-05 | Sun Pharmaceutical Advanced Research Company Ltd | A method for alleviating signs and symptoms of spasticity |
WO2008011016A2 (en) * | 2006-07-18 | 2008-01-24 | Dynogen Pharmaceuticals, Inc. | Treating gastroesophageal reflux disease with 5-ht3- and gaba receptor agonists |
WO2008018275A1 (fr) * | 2006-08-11 | 2008-02-14 | National University Corporation Nagoya University | Agent anti-obésité et son utilisation |
PL2083811T3 (pl) * | 2006-11-22 | 2017-05-31 | Clinical Research Associates, Llc | Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu |
US20150258279A1 (en) | 2008-03-18 | 2015-09-17 | Mallinckrodt Llc | Intrathecal baclofen pharmaceutical dosage forms and related delivery system |
US8969414B2 (en) * | 2009-02-06 | 2015-03-03 | Mallinckrodt Llc | Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products |
JP2012510987A (ja) * | 2008-12-04 | 2012-05-17 | インテック ファーマ リミテッド | ザレプロン胃内滞留性薬剤送達システム |
EP2407162A4 (en) * | 2009-03-13 | 2013-09-18 | Ajinomoto Kk | COMPOSITION FOR ORAL ADMINISTRATION |
US9498440B2 (en) * | 2009-05-22 | 2016-11-22 | Inventia Healthcare Private Limited | Extended release pharmaceutical compositions |
WO2011083150A2 (en) * | 2010-01-07 | 2011-07-14 | Akron Molecules Gmbh | Obesity small molecules |
KR101351181B1 (ko) | 2010-05-11 | 2014-01-14 | 가천대학교 산학협력단 | 단핵식세포계 세포 내에서 age-알부민의 합성 저해 또는 분비 저해에 의한 세포사 유도 저해 방법 |
US8628947B2 (en) | 2010-08-30 | 2014-01-14 | Intervet Inc. | Potomac horse fever isolates |
EP2705842A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
RU2597766C2 (ru) | 2011-03-23 | 2016-09-20 | Раквалиа Фарма Инк. | Агонист рецептора 5-нт4 в качестве прокинетического агента |
FR2991879B1 (fr) | 2012-06-14 | 2014-11-21 | Ethypharm Sa | Formulation pharmaceutique orale de molecules bcs de classe iii |
FR3014692B1 (fr) * | 2013-12-18 | 2016-01-29 | Ethypharm Sa | Compositions pharmaceutiques orales a retention gastrique. |
RU2708686C2 (ru) * | 2014-05-16 | 2019-12-11 | Раквалиа Фарма Инк. | Агонист 5-ht4-рецептора для гастропареза |
WO2016132217A1 (en) * | 2015-02-20 | 2016-08-25 | Osmotica Kereskedelmi Es Szolgaltato Kft | Method of improving gaba-b receptor agonist therapy |
US10172800B2 (en) | 2015-02-20 | 2019-01-08 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form with enhanced pharmacokinetics |
US10987328B2 (en) | 2015-02-20 | 2021-04-27 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
US10300032B2 (en) | 2015-02-20 | 2019-05-28 | Osmotica Kereskedelmi Es Szolgaltato Kft | Controlled release dosage form |
US10987311B2 (en) * | 2017-06-16 | 2021-04-27 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising pyridostigmine |
US10588863B2 (en) * | 2017-06-16 | 2020-03-17 | Kashiv Biosciences, Llc | Extended release compositions comprising pyridostigmine |
ES2861153T3 (es) * | 2018-06-18 | 2021-10-05 | Composiciones de liberación prolongada que comprenden piridostigmina | |
WO2020071546A1 (ja) * | 2018-10-04 | 2020-04-09 | 株式会社 メドレックス | 非水系溶媒により安定化された製剤 |
US11491125B1 (en) | 2021-09-29 | 2022-11-08 | Amneal Pharmaceuticals Llc | Baclofen formulations and methods of minimizing patient exposure to metabolite variations |
WO2023055457A1 (en) * | 2021-09-29 | 2023-04-06 | Amneal Pharmaceuticals Llc | Baclofen-containing granule formulations and reduced patient exposure to metabolite variations |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9308430D0 (en) * | 1993-04-23 | 1993-06-09 | Glaxo Group Ltd | Medicaments |
GB9420784D0 (en) * | 1994-10-14 | 1994-11-30 | Glaxo Group Ltd | Medicaments |
DE69613403T2 (de) * | 1995-12-20 | 2001-10-18 | Fine Chemicals Corp Proprietar | Optisches auflösungsverfahren von 3-(p-chlorophenyl)-glutaramid |
TWI263496B (en) * | 1999-12-10 | 2006-10-11 | Novartis Ag | Pharmaceutical combinations and their use in treating gastrointestinal disorders |
US20040092511A1 (en) * | 1999-12-10 | 2004-05-13 | Billstein Stephan Anthony | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders |
WO2003026631A1 (en) * | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
WO2003094900A1 (en) * | 2002-05-13 | 2003-11-20 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
US7109239B2 (en) * | 2003-08-20 | 2006-09-19 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
-
2004
- 2004-09-08 US US10/935,176 patent/US20050090554A1/en not_active Abandoned
- 2004-09-10 AU AU2004271805A patent/AU2004271805A1/en not_active Abandoned
- 2004-09-10 WO PCT/IB2004/003299 patent/WO2005025559A1/en active Application Filing
- 2004-09-10 EP EP04787558A patent/EP1675581A1/en not_active Withdrawn
- 2004-09-10 JP JP2006525927A patent/JP2007505099A/ja not_active Withdrawn
- 2004-09-10 CA CA002537343A patent/CA2537343A1/en not_active Abandoned
- 2004-09-10 MX MXPA06002572A patent/MXPA06002572A/es not_active Application Discontinuation
-
2006
- 2006-02-26 IL IL173930A patent/IL173930A0/en unknown
- 2006-04-05 NO NO20061541A patent/NO20061541L/no not_active Application Discontinuation
-
2009
- 2009-06-08 US US12/480,287 patent/US20090246233A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA06002572A (es) | 2006-06-05 |
US20050090554A1 (en) | 2005-04-28 |
US20090246233A1 (en) | 2009-10-01 |
AU2004271805A1 (en) | 2005-03-24 |
WO2005025559A1 (en) | 2005-03-24 |
EP1675581A1 (en) | 2006-07-05 |
CA2537343A1 (en) | 2005-03-24 |
JP2007505099A (ja) | 2007-03-08 |
IL173930A0 (en) | 2006-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20061541L (no) | Behandling av gastroparese og ikke-ulceros dyspepsi med GABAB-agonister | |
NO20054546L (no) | Kinazoliner anvendelige som modulatorer av ionekanaler | |
NO20052595L (no) | Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser. | |
NO20054905L (no) | 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika | |
DK1411932T3 (da) | Kombinationsterapi med substituerede oxazolidinoner | |
NO20093464L (no) | Nye medikamentblandinger basert pa anti-cholinergisk effektive forbindelser og beta-mimetika | |
NO20083036L (no) | Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon | |
MY150903A (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain | |
NO20073628L (no) | Pyridoner som er nyttige som inhibitorer av kinaser | |
NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
NO20065847L (no) | Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase | |
NO20054848L (no) | Substituerte p-diaminobenzenderivater | |
NO20012158L (no) | Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav | |
NO20084652L (no) | Deazapuriner anvendelige som inhibitorer av januskinaser | |
NO20074823L (no) | Rasagilin-formuleringer med forbedret innholdsensartethet | |
NO20071742L (no) | Kinazoliner som er nyttige som modulatorer av ionekanaler | |
IL192181A0 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
NO20081942L (no) | Karbamoylbenzotriazolderivater som inhibitorer av lipaser og fosfolipaser | |
DK2040703T3 (da) | Derivater af 2-benzoylimidazopyridiner, fremstilling deraf og terapeutisk anvendelse deraf | |
NO20065835L (no) | Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander | |
DE60306546D1 (de) | Entzündungshemmende 3-arylthio-3-thiazolylalkylamine | |
ATE344262T1 (de) | 2-heteroarylcarbonsäureamide | |
SE0004101D0 (sv) | New use | |
HK1106246A1 (en) | S-tenatoprazole monohydrated sodium salt and the use thereof in therapy s- |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |